OncoMatch/Clinical Trials/NCT05806515
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Is NCT05806515 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin for prostate adenocarcinoma.
Treatment: Carboplatin — This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with high-risk prostate cancer with BRCA1 and BRCA2 gene mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: BRCA1 pathogenic/likely pathogenic variant
Required: BRCA2 pathogenic/likely pathogenic variant
Disease stage
Required: Stage IIIB, IIIC
Grade: grade group 4grade group 5 (gleason sum 8-10)
Performance status
ZUBROD 0–2
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
Absolute neutrophil count >= 1.5 x 10^3/uL; Platelets >= 100 x 10^3/uL (within 28 days prior to registration)
Kidney function
serum creatinine <= the institutional upper limit of normal (IULN) OR measured OR calculated creatinine clearance >= 50 mL/min (Cockcroft-Gault Formula), within 28 days prior to registration
Liver function
AST/ALT <= 3 x institutional upper limit of normal (ULN) (within 28 days prior to registration)
Cardiac function
adequate cardiac function; if cardiac history/symptoms or prior cardiotoxic agents, must be NYHA class 2B or better within 28 days prior to registration
Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration); Platelets >= 100 x 10^3/uL (within 28 days prior to registration); AST/ALT <= 3 x institutional upper limit of normal (ULN) (within 28 days prior to registration); serum creatinine <= the institutional upper limit of normal (IULN) OR measured OR calculated creatinine clearance >= 50 mL/min (Cockcroft-Gault Formula), within 28 days prior to registration; adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification within 28 days prior to registration. To be eligible for this trial, participants must be class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Anchorage Radiation Therapy Center · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify